Assessing the Risk of Bias in Asthma Trials
Author Information
Author(s): Hartling Lisa, Bond Kenneth, Vandermeer Ben, Seida Jennifer, Dryden Donna M., Rowe Brian H.
Primary Institution: University of Alberta
Hypothesis
How reliable is the Risk of Bias tool in evaluating asthma trials?
Conclusion
The Risk of Bias tool shows improved inter-rater reliability and highlights concerns about pharmaceutical industry influence in asthma research.
Supporting Evidence
- 85% of trials had unclear allocation concealment.
- 87% of trials were at high risk of bias.
- 95% of trials were funded by the pharmaceutical industry.
- Inter-rater agreement on RoB assessments was better than previously reported.
- Median time to complete RoB assessments was 21 minutes.
Takeaway
This study looked at how well a tool works to check if asthma studies are fair and found that many studies might be biased because they were funded by drug companies.
Methodology
A systematic review of 107 RCTs was conducted, assessing risk of bias using the RoB tool, Jadad scale, and allocation concealment.
Potential Biases
High risk of bias was found in 87% of studies, primarily due to pharmaceutical industry funding.
Limitations
The study's homogeneity and small sample size may limit the ability to detect differences in effect estimates.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website